Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Viveo R$1.9 billion IPO
We advised Viveo and the selling shareholders on its IPO and São Paulo Stock Exchange listing
LivaNova $345 million equity offering
We advised the underwriters on the SEC-registered offering
New Frontier Health going-private transaction
We are advising the special committee of the board of New Frontier Health in connection with its going-private acquisition
Nurix Therapeutics $150 million at-the-market offering
We advised the sales agent on the stock offering
RxSight $117.6 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing
Tenaya Therapeutics $207 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Colfax $287.3 million secondary offering
We advised certain selling stockholders on the transaction
SOPHiA GENETICS $234 million IPO and $20 million private placement
We advised SOPHiA GENETICS on its IPO, Nasdaq listing and concurrent private placement
Royalty Pharma $1.3 billion senior notes offering
We advised Royalty Pharma on its SEC-registered investment-grade notes offering, including $600 million in social bonds
Natera $584.8 million follow-on offering
We advised the underwriters on the SEC-registered stock offering